Affinity Clinical Research Services Pty Ld in Perth, Western Australia | Medical company
Affinity Clinical Research Services Pty Ld
Locality: Perth, Western Australia
Address: 1/1 Hampden Road NEDLANDS 6009 Perth, WA, Australia
Website: http://affinityresearch.com.au/
Likes: 193
Reviews
to load big map
12.01.2022 Ethics approval received for our upcoming #membranousnephropathy study. Enrollment will be opening soon. #clinicaltrials #nephrology #autoimmunedisease
11.01.2022 Screening appointments are available this Friday. Email [email protected] or phone 0474 769 593 to book. To find out if you are eligible, complete our prescreening questionnaire: https://forms.gle/6cvWTmx6e1svbEMPA
08.01.2022 Now Screening! Perth healthy volunteer trial for a medical cannabis study. This study is investigating a cannabidiol (CBD) sublingual wafer (a fast acting diss...olvable wafer that is placed under the tongue) compared to CBD oil in healthy volunteers. To be eligible participants need to be: 18-65 years old and in good general health Not currently taking any medications Able to attend clinic visits in Nedlands Participants will be remunerated for their time, inconvenience and any out of pocket expenses. Find out if you're eligible, take the survey today https://forms.gle/px7J5FtMR1ykAytu7 #healthyvolunteer #perth #clinicalresearch Affinity Clinical Research Services Pty Ld #research #medicalcannabis #cbdoil
06.01.2022 Olivetree Marketing are doing their part during #LungCancerAwarenessMonth #lungcancerawareness #cancerawareness
06.01.2022 November is #lungcancerawareness month. Did you know that smoking is not the only risk factor to developing lung cancer? It is possible for non-smokers to develop lung cancer. If you have any of the following symptoms, you should have them checked by you doctor:... *Cough *Breathlessness *Chest pain *Coughing up blood *Fatigue *Weight loss *Hoarse voice https://lungfoundation.com.au//cond/lung-cancer/diagnosis/
05.01.2022 Such exiting news! Thank you so much to the patients who volunteered for the aducanumab trials.
